MannKind to Give Oral Presentation on Meal Challenge Results From the Afrezza® With Basal Combination (ABC Study) at 16th Annual ATTD Conference
22 févr. 2023 06h05 HE
|
MannKind
Inhaled Technosphere® Insulin (TI) lowered peak glucose levels 30 minutes faster than injectable rapid-acting insulin delivered through an AID insulin pump and significantly lowered post-prandial...
MannKind Corporation to Hold 2022 Fourth Quarter and Full Year Financial Results Conference Call on February 23, 2023
16 févr. 2023 17h00 HE
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 fourth quarter and full year financial results and its...
Mannkind Corporation to Participate in the SVB Securities Global Biopharma Conference
10 févr. 2023 17h00 HE
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...
MannKind Corporation to Participate in the Lytham Partners Investor Select Conference
24 janv. 2023 06h00 HE
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...
MannKind’s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease
23 janv. 2023 06h05 HE
|
MannKind
Direct delivery of clofazimine to the lungs may provide a treatment option for nontuberculous mycobacterial (NTM) lung disease that potentially overcomes systemic toxicity and lessens side...
MannKind Corporation to Present at 2023 Annual J.P. Morgan Healthcare Conference
05 janv. 2023 06h00 HE
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a company focused on the development and commercialization of innovative...
MannKind to Present Two Posters at 22nd Annual Diabetes Technology Meeting
10 nov. 2022 06h05 HE
|
MannKind
Technosphere® Insulin (TI) peaked 30 minutes faster and significantly reduced postprandial glucose excursions (PPGE) at 60 minutes compared to subcutaneous insulinsThe Afrezza with Basal Combination...
MannKind Corporation Reports 2022 Third Quarter Financial Results
08 nov. 2022 08h00 HE
|
MannKind
3Q 2022 Total Revenues of $32.8 million; +48% vs. 3Q 20213Q 2022 Royalties from Tyvaso DPI of $6.2 million3Q 2022 Commercial Products Net Revenue of $16.3 million; +67% vs. 3Q 2021 DANBURY, Conn. and...
MannKind Corporation to Hold 2022 Third Quarter Financial Results Conference Call on November 8, 2022
01 nov. 2022 06h00 HE
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 third quarter and year to date financial results and its...
MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference
21 sept. 2022 17h00 HE
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative...